Palboxen 125 (Palbociclib)

Palboxen 125 mg (Palbociclib) sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. This medicine is manufactured by Everest Pharmaceutical Limited.

 

Frequently Asked Questions About Palboxen

---

Q: What is Palboxen 125 mg (palbociclib)?

Palboxen 125 is a targeted or biological therapy drug.  Doctors prescribe palbociclib alongside hormone (endocrine) therapy to treat breast cancer. Palbociclib is the generic name for the drug. Its brand name is Ibrance. It belongs to a group of drugs called CDK (cyclin-dependent kinase) inhibitors.

 

Q: How Palboxen 125 mg Work?

Palboxen 125 mg works by blocking these proteins, helping to stop the cancer cells from growing and dividing. When combined with hormone therapies that block the effects of estrogen on cancer cells, palbociclib helps to delay the growth of ER+, HER2-negative breast cancer. for more information visit

 

Q: What happens if I miss a dose of palboxen?

If you miss a palbociclib dose or are sick (vomit) soon after taking it, do not take an extra dose to make up for the one you missed. Keep to your usual amount and speak to someone in your treatment team.

 

---

Dosage & Administration: The recommended dose of Palboxen is 125 mg, taken orally once daily for a period of 21 consecutive days, followed by a 7-day treatment break to complete a full cycle of 28 days. It is important to take Palboxen with food. Administer the recommended dose of an aromatase inhibitor when given with Palboxen 125 mg (Palbociclib). Please consult the Full Prescribing Information for the currently used aromatase inhibitor. When combined with Palbociclib, the recommended dosage of fulvestrant is 500 mg. The initial administration of the recommended dose should take place on Days 1, 15, and 29, with subsequent monthly administrations thereafter. Please refer to the Full Prescribing Information of Fulvestrant. According to current clinical practice standards, pre/perimenopausal women receiving a combination of Palboxen 125 mg (Palbociclib) and fulvestrant therapy should also receive luteinizing hormone-releasing hormone (LHRH) agonists as part of their treatment.

Overdose: It is important to monitor patients for signs of toxicity after an overdose. Treatment of overdose includes monitoring of vital signs as well as observation of the clinical status of the patient.

Storage: Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.